Erythromelalgia in a Patient with Mast Cell Activation Syndrome: Response to Low Dose Naltrexone

Main Article Content

Anastasia O Kurta
Saint Louis University

Leonard B Weinstock
Specialists in Gastroenterology, 11525 Olde Cabin Rd, St. Louis, MO 63141

Natalie Semchyshyn
Saint Louis University

Keywords

erythromelalgia, mast cells, mast cell activation syndrome, MCAS naltrexone, low dose naltrexone

Abstract

Erythromelalgia is a rare condition that may be associated with a variety of underlying conditions and can be refractory to therapy. We report a case of a patient with mast cell activation syndrome (MCAS) who developed erythromelalgia and responded to low dose naltrexone (LDN).

References

1. Thompson GH, Hahn G, Rang M. Erythromelalgia. Clin Orthop Relat Res. 1979;144:249-254.

2. Reed KB, Davis MD. Incidence of erythromelalgia: a population-based study in Olmsted County, Minnesota. J Eur Acad Dermatol Venereol. 2009;23:13. doi: 10.1111/j.1468-3083.2008.02938.x.

3. Yang Y, Wang Y, Li S, et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet. 2004;41:171-174.

4. Molderings GJ, Haenisch B, Bogdanow M, et al. Familial occurrence of systemic mast cell activation disease. PLoS One. 2013;8(9):e76241. doi:10.1371/journal.pone.0076241.10.

5. Afrin LB, Butterfield JH, Raithel M, Molderings GJ. Often seen, rarely recognized: mast cell activation disease – a guide to diagnosis and therapeutic options. Ann Med. 2016;48:190-201.

6. Albers LN, Arbiser JL, Feldman RJ. Treatment of Hailey-Hailey disease with low-dose naltrexone. JAMA Dermatol. 2017;153(10):1018-1020. doi: 10.1001/jamadermatol.2017.2446.

7. Weinstock LB, Myers TL, Steinhoff M, Smith JP. Successful treatment of adult-onset dermatitis herpetiformis with low dose naltrexone. J Med Case Studies. 2017;2(3):27-29.

8. Weinstock LB, Egeberg A, Cottel J, Aldridge L. Low dose naltrexone therapy for psoriasis: open-label case series. SPIN 2019 Abstract: P193

9.https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018932

10. McLaughlin PJ, Zagon IS. Duration of opioid receptor blockade determines biotherapeutic response. Biochem Pharmacol. 2015;97:236-46. doi: 10.1016/j.bcp.2015.06.016.

11. Bruno K, Woller SA, Miller Y, et al. Tarteting toll-like receptor-4 (TLR4)-an emerging therapeutic target for persistent pain states. Pain. 2018;159:1908-1915. doi: 10.1097/j.pain.0000000000001306.

12. Zhang X, Wang Y, Dong H, et al. Induction of Microglial Activation by Mediators Released from Mast Cells. Cell Physiol Biochem. 2016;38:1520-1531. doi: 10.1159/000443093. Epub 2016 Apr 7.

Article Sidebar

PDF
Published
May 8, 2020
DOI https://doi.org/10.25251/skin.4.3.15

Article Details

How to Cite
Kurta, A. O., Weinstock, L. B., & Semchyshyn, N. (2020). Erythromelalgia in a Patient with Mast Cell Activation Syndrome: Response to Low Dose Naltrexone. SKIN The Journal of Cutaneous Medicine, 4(3), 288–291. https://doi.org/10.25251/skin.4.3.15
Issue
Vol. 4 No. 3 (2020)
Section
Brief Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Author Biography

Anastasia O Kurta, Saint Louis University

Dermatology Resident, PGY-4

Saint Louis University?